The therapy referenced
The clinical-stage therapy at the center of the FixCancers network is Targeted Osmotic Lysis (TOL). TOL exploits a specific molecular feature of solid tumor cells, the over-expression of voltage-gated sodium channels, to induce selective osmotic lysis of cancer cells while sparing healthy tissue. The mechanism is published, the regulatory pathway is documented, and eligibility is determined by tumor profile, not by a one-size-fits-all program.
Full technical detail, mechanism diagrams, the regulatory pathway, and the published preclinical and clinical evidence live at FixCancer.org.
Mechanism-targeted vs. integrative wellness
The cross-border cancer clinics that dominate the Tijuana, Baja, and Cancún markets operate on an integrative wellness model. They combine many low-evidence modalities into a multi-week residential program. The model has its supporters, but the clinical posture differs from targeted therapy at fundamental levels.
The integrative model serves patients seeking a comprehensive supportive program. The targeted model serves patients seeking a mechanism-matched intervention. The two are not in competition. They are different products for different clinical questions.
Mechanism-targeted vs. off-label immunotherapy
A second category of cross-border clinic offers off-label immunotherapy, often combining unapproved checkpoint inhibitors, autologous dendritic cell vaccines, NK cell infusions, and CAR-T-adjacent approaches. The clinical pitch is closer to mainstream oncology, but the regulatory pathway and the underlying evidence vary widely by clinic.
The clinical distinction from TOL.
- Selection precision. Targeted therapy aligns to a single, validated molecular feature. Off-label immunotherapy combines many unproven elements without per-patient mechanism matching.
- Reproducibility. Mechanism-targeted intervention reproduces across patients with the same tumor profile. Pooled immunotherapy stacks do not have a standard protocol across clinics.
- Regulatory transparency. TOL operates within published IND, COFEPRIS, and TGA Special Access frameworks. Many off-label immunotherapy stacks operate outside any formal regulatory authorization.
What FixCancers will not do
- No success-rate citations for unapproved therapies. 21 CFR 312.7 prohibits this.
- No patient testimonials for investigational products. FTC Endorsement Guides require typicality disclosures we cannot honestly make.
- No "free treatment plan" download in exchange for an email. The eligibility review is real clinical work that follows real intake.
- No bundled price quoted before eligibility. Pricing is a partner clinic engagement letter, not a website headline.
- No payment to or from any third-party financial referral source. Lender and life-settlement lists are provided without commission.
CORE Medical, Tijuana, Mexico.
The Mexico partner facility for TOL is CORE Medical in Tijuana. CORE operates under COFEPRIS oversight, holds the operational permits required for advanced therapeutic services, and serves as the principal Mexican clinical site for the network referenced from FixCancers.com.
Clinic information, medical team credentials, and visit logistics: coremedical.mx and coremedical.mx/doctors.
The honest summary
FixCancers refers patients to a specific, mechanism-targeted, clinical-stage therapy with a documented regulatory pathway and a named partner facility. The site does not promise outcomes. The site does not bundle wellness modalities into a residential program. The site does not market.
If that is what you are looking for, the intake review is the next step.